scholarly journals Cardioprotective Effects of Telmisartan against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis

2011 ◽  
Vol 7 (8) ◽  
pp. 1077-1092 ◽  
Author(s):  
Vijayakumar Sukumaran ◽  
Punniyakoti T. Veeraveedu ◽  
Narasimman Gurusamy ◽  
Ken'ichi Yamaguchi ◽  
Arun Prasath Lakshmanan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Converting Enzyme ◽  
Autoimmune Myocarditis ◽  
Angiotensin Converting Enzyme 2 ◽  
Mas Receptor ◽  
Cardioprotective Effects ◽  
Experimental Autoimmune Myocarditis ◽  
Experimental Autoimmune

Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases

2014 ◽  
Vol 92 (7) ◽  
pp. 558-565 ◽  
Author(s):  
Nirmal Parajuli ◽  
Tharmarajan Ramprasath ◽  
Vaibhav B. Patel ◽  
Wang Wang ◽  
Brendan Putko ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Ang Ii ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Heart Failure Patients ◽  
Positive Effects ◽  
Mas Receptor

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase that metabolizes several vasoactive peptides, including angiotensin II (Ang-II; a vasoconstrictive/proliferative peptide), which it converts to Ang-(1–7). Ang-(1–7) acts through the Mas receptor to mediate vasodilatory/antiproliferative actions. The renin–angiotensin system involving the ACE–Ang-II–Ang-II type-1 receptor (AT1R) axis is antagonized by the ACE2–Ang-(1–7)–Mas receptor axis. Loss of ACE2 enhances adverse remodeling and susceptibility to pressure and volume overload. Human recombinant ACE2 may act to suppress myocardial hypertrophy, fibrosis, inflammation, and diastolic dysfunction in heart failure patients. The ACE2–Ang-(1–7)–Mas axis may present a new therapeutic target for the treatment of heart failure patients. This review is mainly focused on the analysis of ACE2, including its influence and potentially positive effects, as well as the potential use of human recombinant ACE2 as a novel therapy for the treatment cardiovascular diseases, such as hypertension and heart failure.

Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1–7 mas receptor

2012 ◽  
Vol 351 (2) ◽  
pp. 208-219 ◽  
Author(s):  
Vijayakumar Sukumaran ◽  
Punniyakoti T. Veeraveedu ◽  
Narasimman Gurusamy ◽  
Arun Prasath Lakshmanan ◽  
Ken’ichi Yamaguchi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Autoimmune Myocarditis ◽  
Mas Receptor ◽  
Experimental Autoimmune Myocarditis ◽  
Experimental Autoimmune

Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application

2017 ◽  
Vol 23 (1) ◽  
pp. 89-97 ◽  
Author(s):  
Monika Skrzypiec-Spring ◽  
Katarzyna Haczkiewicz ◽  
Agnieszka Sapa ◽  
Tomasz Piasecki ◽  
Joanna Kwiatkowska ◽  
...  
Keyword(s):  
Heart Failure ◽  
Troponin I ◽  
Heart Function ◽  
Heart Diseases ◽  
Acute Myocarditis ◽  
Study Groups ◽  
Matrix Metalloproteinase 2 ◽  
Autoimmune Myocarditis ◽  
Experimental Autoimmune Myocarditis ◽  
Experimental Autoimmune

Aims: Acute myocarditis is a potentially lethal inflammatory heart disease that frequently precedes the development of dilated cardiomyopathy and subsequent heart failure. At present, there is no effective standardized therapy for acute myocarditis, besides the optimal care of heart failure and arrhythmias in accordance with evidence-based guidelines and specific etiology-driven therapy for infectious myocarditis. Carvedilol has been shown to be cardioprotective by reducing cardiac pro-inflammatory cytokines present in oxidative stress in certain heart diseases. However, effects of carvedilol administration in acute myocarditis with its impact on matrix metalloproteinases’ (MMPs) activation have not been elucidated. Methods and Results: Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks. In comparison to untreated rats (n = 8) with induced myocarditis, carvedilol significantly prevented the left ventricle enlargement and/or systolic dysfunction depending on the dose in study groups. Performed zymography showed enhanced MMP-2 activity in untreated rats, while carvedilol administration reduced alterations. This was accompanied by prevention of troponin I release and myofilaments degradation in cardiac muscle tissue. Additionally, severe inflammatory cell infiltration was detected in the nontreated group. Carvedilol in all doses tested, had no impact on severity of inflammation. The severity of inflammation did not differ between study groups and in relation to the untreated group. Conclusions: The protective effects of carvedilol on heart function observed in the acute phase of experimental autoimmune myocarditis seem to be associated with its ability to decrease MMP-2 activity and subsequently prevent degradation of myofilaments and release of troponin I while not related to suppression of inflammation.

scholarly journals Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure

2020 ◽  
Author(s):  
Iman Razeghian-Jahromi ◽  
Mohammad Javad Zibaeenezhad ◽  
Zhibing Lu ◽  
Elyaspour Zahra ◽  
Razmkhah Mahboobeh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Increased Risk

The angiotensin converting enzyme 2/angiotensin-(1-7)/Mas Receptor axis as a key player in alveolar bone remodeling

Bone ◽  
2019 ◽  
Vol 128 ◽  
pp. 115041 ◽  
Author(s):  
Celso Martins Queiroz-Junior ◽  
Anna Clara Paiva Menezes Santos ◽  
Izabela Galvão ◽  
Giovanna Ribeiro Souto ◽  
Ricardo Alves Mesquita ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Bone Remodeling ◽  
Alveolar Bone ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Mas Receptor ◽  
Alveolar Bone Remodeling

scholarly journals Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure

2008 ◽  
Vol 52 (9) ◽  
pp. 750-754 ◽  
Author(s):  
Slava Epelman ◽  
W.H. Wilson Tang ◽  
Stephen Y. Chen ◽  
Frederick Van Lente ◽  
Gary S. Francis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2
Sign in / Sign up

Export Citation Format

Share Document